Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson’s disease and L-Dopa induced dyskinesia

Lauren Malave,Dustin R. Zuelke,Santiago Uribe-Cano,Lev Starikov,Heike Rebholz,Eitan Friedman,Chuan Qin,Qin Li,Erwan Bezard,Andreas H. Kottmann

DOI: https://doi.org/10.1038/s42003-021-02567-3

IF: 6.548

2021-09-22

Communications Biology

Abstract:Abstract L-Dopa induced dyskinesia (LID) is a debilitating side effect of dopamine replacement therapy for Parkinson’s Disease. The mechanistic underpinnings of LID remain obscure. Here we report that diminished sonic hedgehog (Shh) signaling in the basal ganglia caused by the degeneration of midbrain dopamine neurons facilitates the formation and expression of LID. We find that the pharmacological activation of Smoothened, a downstream effector of Shh, attenuates LID in the neurotoxic 6-OHDA- and genetic aphakia mouse models of Parkinson’s Disease. Employing conditional genetic loss-of-function approaches, we show that reducing Shh secretion from dopamine neurons or Smoothened activity in cholinergic interneurons promotes LID. Conversely, the selective expression of constitutively active Smoothened in cholinergic interneurons is sufficient to render the sensitized aphakia model of Parkinson’s Disease resistant to LID. Furthermore, acute depletion of Shh from dopamine neurons through prolonged optogenetic stimulation in otherwise intact mice and in the absence of L-Dopa produces LID-like involuntary movements. These findings indicate that augmenting Shh signaling in the L-Dopa treated brain may be a promising therapeutic approach for mitigating the dyskinetic side effects of long-term treatment with L-Dopa.

biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: L - Dopa - induced dyskinesia (LID) is a serious side effect in the treatment of Parkinson's disease, and its mechanism is not yet fully understood. The authors hypothesize that the weakened sonic hedgehog (Shh) signal caused by the degeneration of midbrain dopaminergic neurons (DAN) may promote the formation and development of LID. Therefore, the main objective of the paper is to explore whether enhancing the Shh signal can reduce or prevent LID and verify the validity of this hypothesis in multiple Parkinson's disease models.

Specifically, researchers activated the key effector molecule Smoothened (Smo) in the Shh signaling pathway by pharmacological methods and observed its impact on LID. They used the 6 - hydroxy - dopamine (6 - OHDA) - induced mouse model, the genetic aphakia mouse model (aphakia, AK−/−), and non - human primate models to test whether increasing the Shh signal can reduce the abnormal involuntary movements (AIMs) caused by L - Dopa. In addition, the study also explored the interaction between the Shh signal in dopaminergic neurons and cholinergic interneurons (CIN) and how this interaction affects the occurrence of LID.

Through these experiments, researchers hope to reveal the mechanism of the Shh signal in regulating LID and provide a theoretical basis for the development of new treatment methods.